BioNTech Moves to Full Control as CureVac Tender Clears Major Hurdles

BioNTech Wins a Clear Majority

The takeover was effectively settled through the exchange tender. By the close of the first acceptance window, 184,071,410 CureVac shares had been tendered, representing about 81.74% of the issued and outstanding capital. This level meets the minimum acceptance threshold, clearing the path for the subsequent reorganization.

Under the deal, BioNTech will deliver American Depositary Shares (ADS) to those holders who accepted. The exchange ratio is Read more...